<h2>IONQ: BofA initiates Buy as $60 target boosts momentum</h2><p>IonQ shares were in focus Monday after Bank of America initiated coverage of <strong>$IONQ</strong> with a <strong>Buy</strong> rating and a <strong>$60 price target</strong> on September 28, 2026. The stock was down 0.8% in premarket trading, but the new coverage gives traders a fresh catalyst tied to growing confidence in quantum computing commercialization.</p><h3>What Happened</h3><p>Bank of America’s initiation puts a major Wall Street bank behind the quantum computing name at a time when investors are looking for proof that the category can move from technical progress to commercial revenue. The call arrives just days after IonQ highlighted a breakthrough in quantum error correction, adding to the stock’s recent flow of positive headlines.</p><p>The market reaction was muted at the open, with shares slipping in premarket trading even after the upgrade. That kind of setup is common in high-volatility growth names: the strategic narrative improves first, while price action often lags or whips around as traders digest valuation, execution risk, and the timing of monetization.</p><h3>Analyst Take</h3><p>The new Buy rating matters because it signals that a large institutional shop sees room for IonQ to keep winning credibility beyond the speculative quantum trade. For retail investors and active traders, that can be enough to keep the stock on momentum screens, especially when fresh coverage lands alongside a headline-grabbing product or technology update.</p><p>The $60 target also helps frame the stock’s upside narrative for portfolio managers evaluating whether quantum exposure belongs in a growth sleeve or as a trading position. It does not eliminate the core debate around commercialization, but it does suggest the Street sees a more durable path to value creation than the market may have priced in before the note.</p><h3>What to Watch</h3><ul><li>Whether $IONQ can hold gains after the initial reaction to the Bank of America initiation.</li><li>Follow-through from other brokers, since more upgrades or target raises could extend the move.</li><li>Management commentary on commercialization timelines, customer traction, and deployment milestones.</li><li>Whether recent technical and product announcements continue to reinforce the investment case.</li><li>Broader risk appetite for high-beta quantum computing names, which can amplify both rallies and reversals.</li></ul><p>For now, the takeaway is straightforward: Bank of America’s Buy call gives <strong>$IONQ</strong> another institutional validation point, and that can support near-term trading interest even if the stock remains volatile.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/news/4647505-ionq-in-focus-as-bofa-starts-with-buy-rating" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – IonQ in focus as BofA starts with Buy rating (IONQ:NYSE) | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/27/ionq-major-breakthrough-invest-buy-stock/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – IonQ Just Announced a Major Breakthrough. Should Investors Buy the Stock Now? | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://finance.yahoo.com/technology/ai/articles/top-quantum-computing-stocks-september-211247698.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>finance.yahoo.com – Top Quantum Computing Stocks For September 2026</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/news/4647387-find-alpha-in-the-revenue-growth-fog-goldman" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Find alpha in the revenue growth fog - Goldman | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/26/nvidia-and-these-other-stocks-are-on-sale-bank-of-america-says.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Nvidia and these other stocks are on sale, Bank of America says</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://ca.investing.com/news/economy-news/trump-rejects-iran-proposal-openai-pause-weighs-on-tech--whats-moving-markets-4855172" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>ca.investing.com – Trump rejects Iran proposal; OpenAI pause weighs on tech - what’s moving markets By Investing.com</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Fresh Wall Street coverage from Bank of America adds institutional support for IonQ as traders focus on quantum computing commercialization.

IONQ: BofA initiates Buy as $60 target boosts momentum

<h2>Micron $MU eyes 86% margin on $50B Q4 print</h2><p>Micron Technology $MU heads into Wednesday’s fiscal Q4 report with one of the most aggressive outlooks in memory-chip history: roughly $50.0 billion in revenue and about 86% gross margin. That combination has made the stock a high-stakes read on AI demand, with traders treating the print as a key test for the broader AI infrastructure trade.</p><h3>What Happened</h3><p>Micron’s late-June guidance set the bar unusually high for the August-to-September quarter, calling for revenue of $50.0 billion, plus or minus $1.0 billion, and gross margin of approximately 86%. The company also guided for non-GAAP EPS of $31.00, plus or minus $1.00, a level that reflects exceptionally strong pricing and mix in DRAM and high-bandwidth memory.</p><p>The quarter being reported is already complete, and the market is now focused on whether Micron can confirm that AI-driven demand translated into the kind of profitability management outlined in June. Options pricing suggests investors are bracing for a meaningful post-earnings move, which is why the stock has become one of the most watched data points on the calendar this week.</p><h3>Analyst Take</h3><p>Wall Street has been leaning constructive into the print. Citi recently lifted its price target on Micron to $1,300 from $1,150 and raised its estimates, citing stronger DRAM pricing and tighter supply conditions. In that note, Citi modeled fiscal Q4 sales of $51 billion and EPS of $31.45, both above consensus, signaling that the firm sees room for Micron to beat or at least reinforce its already elevated guide.</p><p>The key takeaway for investors is not just the headline numbers, but the durability of those margins. An 86% gross margin is extraordinary for a memory maker, where pricing has historically been far more cyclical and volatile. If Micron prints near guide and backs it up with constructive commentary on pricing, supply, and AI demand, it could validate the entire memory upcycle narrative.</p><h3>What to Watch</h3><ul><li>Revenue versus the $50.0 billion guide, since even a small miss or beat will shape sentiment around demand strength.</li><li>Gross margin near 86%, the most important proof point for whether AI-led pricing is holding.</li><li>Management commentary on DRAM and high-bandwidth memory, which will help determine if current pricing is durable.</li><li>Forward guidance, especially whether Micron keeps the market’s expectations elevated into the next quarter.</li><li>Volatility after the print, since the options market is already pricing a large move and the result may steer AI semis and infrastructure names.</li></ul><p>For retail investors, active traders, and portfolio managers, the setup is simple: Micron is no longer just a memory stock on earnings night. It is a read-through on whether AI hardware demand can support peak-cycle economics for one of the market’s most important suppliers.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/27/micron-guided-to-an-86-gross-margin-no-memory-maker-has-ever-held-a-number-like-that-for-long/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Micron Guided to an 86% Gross Margin. No Memory Maker Has Ever Held a Number Like That for Long. | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/article/4949815-micron-nike-to-headline-earnings-next-week-gdp-numbers-awaited" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Micron, Nike To Headline Earnings Next Week, GDP Numbers Awaited | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://in.investing.com/news/stock-market-news/5-big-analyst-ai-moves-muse-ai-seen-as-major-catalyst-for-meta-msft-upgraded-5607349" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>in.investing.com – 5 big analyst AI moves: Muse AI seen as major catalyst for Meta; MSFT upgraded By Investing.com</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.investing.com/analysis/what-metas-muse-tells-us-about-the-agentic-era-200688435" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>investing.com – Market Analysis &amp;amp; Forecast - Investing.com</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://ca.investing.com/news/stock-market-news/5-big-analyst-ai-moves-muse-ai-seen-as-major-catalyst-for-meta-msft-upgraded-4854282" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>ca.investing.com – 5 big analyst AI moves: Muse AI seen as major catalyst for Meta; MSFT upgraded By Investing.com</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/25/microsoft-gives-copilot-a-much-needed-overhaul-and-the-stock-deservedly-soars.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Microsoft gives Copilot a much-needed overhaul, and the stock deservedly soars</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Micron’s rare margin setup could reset AI-memory expectations and move the whole infrastructure trade.

Micron $MU eyes 86% margin on $50B Q4 print

<h2>Humana $HUM jumps 6% on Barclays upgrade ahead of Star ratings</h2><p>Humana shares rose 6% on Friday after Barclays upgraded the stock to <strong>Overweight</strong> from <strong>Equal Weight</strong> ahead of the upcoming Medicare Star ratings release. The stock briefly climbed as much as 9% intraday, its biggest single-day gain since June, as traders positioned for a possible ratings-driven rebound.</p><h3>What Happened</h3><p>Barclays analyst Andrew Mok said the firm has become more constructive on Humana’s Medicare Star ratings outlook, boosting the stock ahead of the October catalyst expected around Oct. 8. The call centers on the possibility that Humana can flip several contracts into bonus status, a development that would be meaningful because Star ratings feed directly into reimbursement levels for Medicare Advantage insurers.</p><p>That matters especially for Humana because Medicare Advantage is the core of the company’s business and a higher rating can translate into better revenue capture and stronger pricing power. The market clearly treated the upgrade as a high-conviction near-term catalyst, with the stock seeing a sharp repricing on the session.</p><h3>Analyst Take</h3><p>Barclays’ upgrade signals a bigger shift than a routine rating tweak. By moving to Overweight, the firm is effectively saying the stock’s risk-reward has improved enough to justify owning it ahead of a binary event that could reframe earnings expectations and investor sentiment.</p><p>The key point for traders is that the move was not driven by a fresh earnings beat, but by anticipation of a policy-linked catalyst. In managed care, that kind of setup can matter just as much as quarterly results because the Star rating framework influences profitability across a large book of membership.</p><ul><li><strong>Positive setup:</strong> Barclays sees improved odds of a rebound in Medicare Star ratings.</li><li><strong>Stock reaction:</strong> HUM rose 6% and traded up as much as 9% intraday.</li><li><strong>Why it matters:</strong> Better ratings can lift reimbursement and support revenue growth.</li></ul><h3>What to Watch</h3><p>The immediate focus is the Star ratings release expected around Oct. 8. If Humana lands better-than-expected results, the stock could extend its gains as investors price in stronger reimbursement prospects and a cleaner operating backdrop into the next cycle.</p><p>Portfolio managers will also want to watch whether the rally holds into the announcement or fades as event risk gets fully priced. For active traders, Humana now sits in a classic catalyst trade: upside tied to a specific regulatory and reimbursement outcome, with the main question being whether Barclays is early or right.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://in.investing.com/news/stock-market-news/humana-surges-barclays-bets-big-on-medicare-star-ratings-rebound-5607115" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>in.investing.com – Humana surges: Barclays bets big on Medicare star ratings rebound By Investing.com</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://finance.yahoo.com/healthcare/articles/q2-earnings-outperformers-unitedhealth-nyse-165658321.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>finance.yahoo.com – Q2 Earnings Outperformers: UnitedHealth (NYSE:UNH) And The Rest Of The Health Insurance Providers Stocks</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://finance.yahoo.com/healthcare/articles/does-unitedhealth-cao-hire-reveal-231234809.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>finance.yahoo.com – Does UnitedHealth’s New CAO Hire Reveal a Deeper Shift in Efficiency Strategy for UNH?</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/25/biggest-wall-street-analyst-calls-friday.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Biggest Wall Street analyst calls Friday</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://finance.yahoo.com/healthcare/articles/globe-lifes-health-premium-growth-135200638.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>finance.yahoo.com – Globe Life's Health Premium Growth Strengthens 2026 Outlook</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://in.investing.com/news/stock-market-news/truist-maintains-amn-healthcare-stock-rating-on-travel-nurse-demand-93CH-5606363" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>in.investing.com – Truist maintains AMN Healthcare stock rating on travel nurse demand By Investing.com</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Barclays sees a rebound in Medicare Star ratings as a near-term catalyst that could improve Humana’s reimbursement outlook and sentiment.

Humana $HUM jumps 6% on Barclays upgrade ahead of Star ratings

<h2>COST Q4 EPS Jumps 15% to $6.75 as Costco Tops Estimates</h2><p>Costco Wholesale ($COST) reported fiscal fourth-quarter earnings of $6.75 per diluted share for the 16-week period ended August 30, 2026, up 15% from a year earlier and ahead of expectations. The beat matters because it came even after backing out a 15-cent tariff-refund benefit, pointing to strong underlying demand and healthy membership momentum heading into the holiday season.</p><h3>What Happened</h3><p>Costco posted net income of $2.998 billion, or $6.75 a share, versus $2.610 billion, or $5.87 a share, in the same quarter last year. Net sales rose 11.2% to $93.9 billion from $84.4 billion, extending the company’s long-running pattern of steady top-line growth.</p><p>The quality of the print is what stood out. Management’s results included a 15-cent per-share benefit from tariff refunds, but the company still cleared consensus without relying entirely on that one-time tailwind. That suggests the core engine remained intact: traffic, basket strength, and a resilient value proposition that continues to draw shoppers despite a more cautious consumer backdrop.</p><p>Membership remained a key support pillar. Membership fee income rose 7.3% to $1.85 billion, while both worldwide and U.S./Canada renewal rates improved sequentially. For investors, that matters because Costco’s model depends on repeat visits, renewals, and the ability to convert traffic into steady fee income.</p><p>For the full fiscal year, Costco generated $297.2 billion in net sales, up 10.1% from $269.9 billion a year earlier. That keeps the warehouse club operator firmly in the top tier of U.S. retail growth names as the sector heads into the holiday quarter.</p><h3>Analyst Take</h3><p>Analysts viewed the print as evidence that Costco is still executing at a premium level. The earnings beat, combined with the improvement in renewal rates, helped push analysts to lift their price target on the stock.</p><p>The key takeaway for the Street is that Costco did not need a perfect macro environment to deliver. Even after stripping out the tariff-refund boost, earnings still beat expectations, underscoring durable demand from households that continue to prioritize value, convenience, and bulk purchasing.</p><p>That makes $COST an important read-through for retail sentiment overall. If Costco can keep growing sales, fees, and renewals at this pace, it reinforces the idea that higher-income and middle-income consumers are still spending selectively, especially at operators with clear savings propositions.</p><h3>What to Watch</h3><ul><li>Holiday-quarter traffic trends, especially whether value-seeking shoppers continue to trade up to warehouse clubs.</li><li>Membership renewal rates, which remain one of the best indicators of Costco’s long-term moat.</li><li>Whether tariff-related benefits fade without disrupting margin durability.</li><li>How analysts revise estimates after the beat and whether higher targets translate into broader institutional buying.</li><li>Same-store sales and digital momentum, which will show whether Costco is gaining share beyond the core warehouse channel.</li></ul><p>For traders, the message is straightforward: $COST delivered a cleaner-than-expected beat, and the durability of the membership model is still doing the heavy lifting. For long-only investors, the report keeps Costco on the shortlist of defensive growth names with real earnings power going into year-end.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.globenewswire.com/news-release/2026/09/24/3368754/0/en/costco-wholesale-corporation-reports-fourth-quarter-and-fiscal-year-2026-operating-results.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>globenewswire.com – Costco Wholesale Corporation Reports Fourth Quarter and</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/24/costco-makes-progress-on-a-key-membership-metric-heres-our-new-price-target-on-the-stock.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Costco makes progress on a key membership metric. Here's our new price target on the stock</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/breakfast-news/2026/09/24/breakfast-news-will-ai-buy-your-cheerios-next/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Breakfast News: Will AI Buy Your Cheerios Next? | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/05/28/q1-earnings-season-winding-down-stocks-nvda/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Q1 Earnings Season Is Winding Down. Here Are the 5 Stocks That Defined It. | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://finance.yahoo.com/markets/stocks/articles/autozone-q4-earnings-beat-estimates-135200571.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>finance.yahoo.com – AutoZone Q4 Earnings Beat Estimates on Tariff Refunds, Sales Miss</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/24/why-we-like-starbucks-latest-turnaround-move-plus-two-more-wins-for-eli-lilly.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Costco beat fiscal Q4 EPS expectations, reinforcing member loyalty and consumer resilience into the holiday season.

COST Q4 EPS jumps 15% to $6.75 on strong demand

<h2>10-Year Treasury Yield Hits 19-Year High, Pressuring $TLT and Futures</h2><p>U.S. stock futures were under pressure Thursday as the 10-year Treasury yield pushed higher after touching a 19-year high in the prior session. The move reflects a sharp repricing of Fed expectations after stronger economic data and hawkish policy signals stoked bets that rates will stay elevated longer than traders had expected.</p><h3>What Happened</h3><p>The benchmark 10-year Treasury yield rose to 5.124% in early trading after reaching a 19-year high on Wednesday, extending a bond selloff that sent yields above 5% for the first time in years. The rise came after a stronger-than-expected U.S. business activity report, including a services reading that hit a nearly five-year high and a manufacturing print at a four-year-plus peak.</p><p>Those data points reinforced the view that the economy remains hot enough to keep inflation sticky, which has pushed traders to raise the odds of another Federal Reserve rate hike. Dow, S&amp;P 500, and Nasdaq futures all moved lower as higher yields hit risk appetite and compressed valuations, especially in rate-sensitive sectors.</p><p>The bond move matters directly for $TLT, the long-duration Treasury ETF, which typically weakens when yields rise and bond prices fall. A 19-year high in the 10-year yield is not just a headline move; it is a macro signal that investors are demanding much higher compensation to hold duration.</p><h3>Analyst Take</h3><p>The market is treating the yield spike as a warning that the Fed may need to stay restrictive for longer, or even tighten again, if growth and inflation stay firm. That is bearish for equities broadly because higher discount rates pressure future earnings valuations, with long-duration growth names and the broader index complex most exposed.</p><p>For traders, the key message is that this is not an isolated bond move. The yield breakout is feeding through to equities, risk premiums, and sector rotation, with defensive and value-oriented corners likely to hold up better than the most rate-sensitive areas.</p><h3>What to Watch</h3><ul><li>Whether the 10-year yield can hold above the 5% area or extend higher, which would deepen valuation pressure on stocks.</li><li>Any follow-through in Fed rate-hike pricing, especially after the latest strong economic data.</li><li>Equity futures reaction into the cash open, particularly in rate-sensitive sectors and megacap growth.</li><li>$TLT price action, since continued yield upside would likely keep downward pressure on long-duration Treasurys.</li><li>Additional economic releases and Fed commentary that could either validate or challenge the hawkish repricing.</li></ul>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/24/us-treasury-yields-bonds-fed-inflation.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – 10-year Treasury yield continues to rise from 19-year high</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/23/stock-market-today-live-updates.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Stock market today: Live updates</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/23/bond-yields-spike-and-stocks-drop-plus-why-boeing-is-bucking-the-trend.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Bond yields spike and stocks drop — plus, why Boeing is bucking the trend</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/24/trump-xi-china-visit-tariff-iran-yields-.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – A tarmac welcome buys U.S.-China truce a longer runway</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://finance.yahoo.com/markets/article/10-year-treasury-yield-hits-highest-level-since-2007-as-market-prices-in-another-fed-rate-hike-152744538.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>finance.yahoo.com – 10-year Treasury yield hits highest level since 2007 as market prices in another Fed rate hike</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/coverage/stock-market-today/2026/09/23/stock-market-midday-sept-23-stocks-slip-as-treasury-yields-hit-19-year-high/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Stock Market Midday, Sept. 23: Stocks Slip as Treasury Yields Hit 19-Year High | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Rising Treasury yields are squeezing equity futures and extending the bond selloff as traders price in a more restrictive Fed path.

10-Year Yield Hits 19-Year High; $TLT Pressured

<h2>VKTX surges 35.7% on VK2735 obesity data</h2><p>Viking Therapeutics $VKTX jumped 35.67% after reporting positive maintenance-study results for its experimental obesity drug VK2735. The move came as investors repriced the stock around data showing strong weight loss, no clear plateau, and the potential for less frequent dosing.</p><h3>What Happened</h3><p>Viking said patients receiving weekly doses of VK2735 posted roughly 16% to 19% weight loss after 21 weeks, versus about 0% for placebo. The company also reported that weight loss continued to build over time, with no evidence of a plateau, a key signal in a market that rewards drugs with durable efficacy.</p><p>The broader maintenance readout added another layer of support. Viking reported 22% placebo-adjusted weight loss at week 33 in a weekly-dosing cohort, while also showing that patients who moved to less frequent dosing could preserve much of their prior weight loss. That matters because investors have been looking for obesity treatments that can combine strong efficacy with better convenience and adherence.</p><p>The market reaction was immediate. Shares closed up 35.7% at $40.85, marking the stock’s biggest one-day percentage gain in more than two years and underscoring how sensitive obesity names remain to trial data.</p><h3>Analyst Take</h3><p>The message from traders was simple: VK2735 looks more credible as a GLP-1/GIP competitor after this readout. In a weight-loss market dominated by intense competition, a double-digit efficacy profile paired with maintenance durability can materially change how the street values a clinical-stage biotech.</p><p>For active investors, the key takeaway is not just the headline weight loss figure. It is the combination of efficacy, progression over time, and flexible maintenance dosing that strengthens the program’s commercial case. That kind of setup can drive a sharp single-session rerating, especially when the market is focused on the next credible challenger in obesity therapeutics.</p><h3>What to Watch</h3><ul><li>Whether Viking can sustain investor confidence as it advances VK2735 into later-stage development.</li><li>How the safety and tolerability profile holds up as dosing periods extend.</li><li>Whether competitors in the GLP-1 and GIP space can match or exceed the durability and maintenance data.</li><li>Whether the stock holds its gains or sees volatility as traders digest the size of the move.</li></ul><p>For portfolio managers, the next catalyst is whether this trial momentum translates into a clearer path toward Phase 3 execution and a stronger competitive position in obesity medicine.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/23/why-viking-therapeutics-stock-skyrocketed-on-tues/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Why Viking Therapeutics Stock Skyrocketed on Tuesday | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.prnewswire.com/news-releases/viking-therapeutics-announces-positive-topline-results-from-maintenance-study-of-glp-1gip-agonist-vk2735-demonstrating-the-promise-of-multiple-maintenance-dosing-regimens-302885584.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>prnewswire.com – Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/news/4645533-viking-thera-stock-jumps-obesity-drug-data" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Viking Thera stock jumps on obesity drug data (VKTX:NASDAQ) | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/video/2026/09/22/viking-therapeutics-shares-surge-on-weight-loss-drug-trial.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Viking Therapeutics' shares surge on weight loss drug trial</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.globenewswire.com/news-release/2026/09/22/3366586/0/en/today-s-best-stocks-to-watch-weight-loss-wars-biotech-and-critical-minerals.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>globenewswire.com – Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.globenewswire.com/news-release/2026/09/22/3366613/0/en/zealand-pharma-announces-initiation-of-the-registrational-phase-3-zupreme-program-of-petrelintide-in-people-with-overweight-or-obesity.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>globenewswire.com – Zealand Pharma announces initiation of the registrational</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Positive maintenance-study results and durable weight loss just gave Viking a major credibility boost in the GLP-1 race.

VKTX surges 35.7% on VK2735 obesity data

<h2 data-level="2">META jumps 11.3% to $741.25 as Muse hits No. 1 and Wells Fargo lifts target to $796</h2><p>$META surged 11.3% on Monday to close at $741.25 after Meta’s Muse AI assistant reached the top spot on Apple’s App Store and Wells Fargo raised its price target to $796 from $640. The move added about $192 billion in market value in a single session and signaled a sharp reassessment of Meta’s AI consumer strategy.</p><h3 data-level="3">What Happened</h3><p>The catalyst was a one-two punch: early adoption for Meta’s new Muse AI product and a fresh bullish call from Wells Fargo. Investors piled in after reports showed Muse climbing to No. 1 on Apple’s App Store, giving Meta a visible consumer-facing AI win just weeks after launch.</p><p>Momentum in the stock was fast and broad. Meta’s advance put the shares well above the prior session’s levels and sent the company’s market cap higher by roughly $192 billion, while trading volume jumped far above typical levels. The rally also lifted sentiment heading into Meta’s Connect event, where traders are watching for more detail on the company’s AI roadmap.</p><p>Recent launches were central to the narrative. Wells Fargo pointed to Meta’s Muse Spark LLM and the Muse assistant as evidence that the company now has a stronger story to tell around AI products and services.</p><h3 data-level="3">Analyst Take</h3><p>Wells Fargo’s Ken Gawrelski raised his target from $640 to $796, effectively resetting the bar for Meta’s equity story. That matters because the new target sits above the prior close but still leaves room for additional upside if Muse keeps gaining users and Meta converts that attention into monetization.</p><p>The call reflects a shift from “AI investment story” to “AI product story.” For portfolio managers, that distinction is critical: the market is no longer only valuing Meta on ad strength and capex discipline, but also on whether it can turn consumer AI adoption into a durable revenue stream.</p><p>For active traders, the move confirms that Muse has become a real sentiment driver, not just a feature launch. The combination of a top App Store ranking and a higher target gave bulls a clean catalyst to chase.</p><h3 data-level="3">What to Watch</h3><ul><li><p>Whether Muse can stay near the top of Apple’s App Store and keep download momentum intact.</p></li><li><p>Any new product or monetization details from Meta’s upcoming Connect event.</p></li><li><p>Follow-through from other analysts after Wells Fargo’s target hike.</p></li><li><p>Whether $META can hold gains above the post-rally level and build a new trading range.</p></li><li><p>Signs that Muse adoption is broadening beyond early curiosity into repeated use.</p></li></ul><p>The key question now is whether Monday’s surge was a one-day re-rating or the start of a larger AI-driven reset for Meta’s valuation. With the stock still below the new $796 target, bulls have a fresh data point to argue that the market is underestimating Meta’s consumer AI opportunity.</p><h3 data-level="3">Sources</h3><ul><li><p><u><a target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/technology/article/meta-stock-soars-11-on-price-target-increase-muse-ai-downloads-180423756.html">finance.yahoo.com – Meta stock soars 11% on price target increase, Muse AI downloads</a></u></p></li><li><p><u><a target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/markets/stocks/article/why-muse-really-just-added-billions-to-metas-market-cap-and-to-mark-zuckerbergs-net-worth-094853229.html">finance.yahoo.com – Why Muse really just added billions to Meta's market cap and to Mark Zuckerberg's net worth</a></u></p></li><li><p><u><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fool.com/coverage/stock-market-today/2026/09/21/stock-market-today-sept-21-meta-surges-on-excitement-over-muse-personal-ai-agent/">fool.com – Stock Market Today, Sept. 21: Meta Surges on Excitement Over Muse Personal AI Agent | The Motley Fool</a></u></p></li><li><p><u><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fool.com/investing/2026/09/22/meta-stock-is-still-too-cheap/">fool.com – Meta Stock Is Still Too Cheap | The Motley Fool</a></u></p></li><li><p><u><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/09/22/cnbc-daily-open-ai-meta-muse.html">cnbc.com – CNBC Daily Open: AI trade goes Meta after Muse launch</a></u></p></li><li><p><u><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/shopify-to-use-meta-s-muse-for-agentic-checkout-451ab392">marketwatch.com – Shopify to Use Meta's Muse for Agentic Checkout - MarketWatch</a></u></p></li></ul><p></p>

Meta’s AI consumer push just got a market re-rating, with Muse adoption and a higher Wall Street target driving a one-day cap expansion.

META jumps 11.3% to $741.25 on Muse AI momentum, Wells Fargo boost

<h2>Paramount $PARA gains 6.7% as California settlement talks lift merger odds</h2><p>Paramount Skydance shares rose 6.7% to $10.89 in premarket trading Monday after The Wall Street Journal reported the company has been in advanced settlement talks with California’s attorney general over the antitrust lawsuit blocking its $81 billion merger with Warner Bros. Discovery. Warner Bros. Discovery also moved higher, climbing 7.6% to $29.90, as traders priced in a better chance of deal completion.</p><h3>What Happened</h3><p>The key development is a potential compromise with California regulators, which could remove one of the last major obstacles to the transaction. The discussions reportedly include concessions such as a possible $1.5 billion investment in production in California, along with commitments tied to studio operations and future movie output.</p><p>For investors, the market reaction is straightforward: the settlement narrative reduces regulatory uncertainty and brings the merger one step closer to closing. That matters because the antitrust lawsuit has been a persistent overhang on both stocks and has kept merger-arbitrage expectations sensitive to every legal update.</p><ul><li>$PARA was up 6.7% to $10.89 in premarket trading.</li><li>Warner Bros. Discovery rose 7.6% to $29.90.</li><li>The reported settlement discussions focus on clearing antitrust hurdles tied to the $81 billion deal.</li></ul><h3>Analyst Take</h3><p>The move reflects a classic event-driven setup: when regulatory risk falls, the probability of deal closure rises, and the stock usually re-rates quickly. For active traders, that makes $PARA a headline-sensitive name with upside tied to legal progress, while portfolio managers may view the stock as a direct proxy for merger execution risk.</p><p>The reported concessions are also meaningful because they suggest both sides are working toward a practical solution rather than extending the fight. If the parties can lock in an agreement, it could accelerate the timeline and potentially narrow the gap between current pricing and the market’s view of deal value.</p><h3>What to Watch</h3><ul><li>Any formal confirmation of a settlement framework from Paramount or California officials.</li><li>Whether the reported $1.5 billion California investment remains part of the final terms.</li><li>Additional conditions around studio ownership, movie production commitments, or governance.</li><li>State-level resistance from other regulators or attorneys general that could complicate approval.</li><li>Whether $PARA can hold gains beyond the initial headline pop as traders reassess merger odds.</li></ul><p>For now, $PARA is trading like a stock with improving deal visibility: the catalyst is real, the regulatory path is clearer, and the next update from the legal front could drive the shares again.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.marketwatch.com/story/paramount-skydance-warner-bros-shares-gain-on-wsj-report-of-california-settlement-talks-c29cff98" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>marketwatch.com – Paramount Skydance, Warner Bros. Shares Gain on WSJ Report of California Settlement Talks - MarketWatch</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/video/2026/09/21/paramount-and-california-ag-discussed-concessions-to-settle-suit-blocking-wbd-merger-report.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Paramount and California AG discussed concessions to settle suit blocking WBD merger: Report</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/article/4948239-busy-week-for-geopolitics" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Busy Week For Geopolitics | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/news/4644569-key-deals-this-week-spgi-pso-gehc-and-more" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Key deals this week: SPGI, PSO, GEHC and more (NYSE:SPGI) | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/20/buy-stocks-such-as-warner-music-morgan-stanley-says-.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Buy stocks such as Warner Music, Morgan Stanley says</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/21/chinese-biopharma-stocks-jump-as-us-plans-to-continue-drug-licensing-deals-.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Chinese biopharma stocks jump as U.S. plans to continue drug licensing deals</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

$PARA jumped after a report said settlement discussions with California’s attorney general could remove a major merger hurdle.

Paramount PARA gains 6.7% on California settlement talks

<h2>STLD Pre-Announces Q3 EPS of $5.34-$5.38, Tops Prior Quarters</h2><p>Steel Dynamics $STLD pre-announced third-quarter earnings per share of $5.34 to $5.38, giving investors an early read on results ahead of the official print. The update points to stronger-than-expected profitability, driven by metal margin expansion and record steel shipments.</p><h3>What Happened</h3><p>Steel Dynamics said its Q3 earnings should land in a tight range, a move that typically acts as a high-conviction signal from management before quarterly results are released. The guidance range of $5.34 to $5.38 per diluted share sets a clear benchmark for traders and portfolio managers heading into earnings season.</p><p>The backdrop matters. Pre-announcements from industrial companies usually reflect meaningful visibility into end-market demand, pricing, and operating trends. In Steel Dynamics' case, the key positives were margin improvement and record shipments, both of which suggest the company is converting volume into earnings power more efficiently than the market may have expected.</p><h3>Analyst Take</h3><p>The market is likely to view the update as an upside data point rather than a routine check-in. Even without a formal full-quarter report yet, the guidance narrows the range of possible outcomes and lowers the odds of a major negative surprise when earnings are released.</p><p>For retail investors, the message is straightforward: profitability appears to be tracking above prior-quarter levels, and the company is still seeing enough demand to push shipments to record territory. For active traders, that combination can keep momentum in the name, especially if the broader steel group is firm.</p><p>For portfolio managers, the more important question is whether the margin strength is cyclical, sustainable, or both. If pricing remains favorable and shipment volumes stay elevated, Steel Dynamics could continue to outperform even in a choppy macro tape.</p><h3>What to Watch</h3><ul><li>The official Q3 earnings release and management commentary on margins.</li><li>Whether record steel shipments continue into the next quarter.</li><li>Any sign that pricing strength is holding versus fading.</li><li>How the stock trades relative to other steel and industrial names after the pre-announcement.</li><li>Forward guidance for Q4 and any update on demand trends across end markets.</li></ul><p>For now, $STLD has delivered a concrete earnings upside marker ahead of the full report, and that is exactly the kind of catalyst the market can trade on before numbers hit the tape.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.benzinga.com/news/26/09/61869200/reported-earlier-steel-dynamics-sees-q3-gaap-eps-5-34-5-38-vs-5-66-est" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>benzinga.com – Reported earlier, Steel Dynamics Sees Q3 GAAP EPS $5.34-$5.38 vs $5.66 Est - Steel Dynamics (NASDAQ:STLD) - Benzinga</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://finance.yahoo.com/markets/stocks/articles/steel-dynamics-stld-bargain-q3-171154335.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>finance.yahoo.com – Is Steel Dynamics (STLD) A Bargain After Its New Q3 2026 Earnings Guidance?</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/article/4948118-steel-dynamics-q3-preannouncement-nothing-unusual" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Steel Dynamics Q3 Pre-Announcement Is Nothing Unusual (NASDAQ:STLD)</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/18/stock-market-next-week-outlook-for-sept-21-25-2026.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Stock market next week: Outlook for Sept. 21-25, 2026</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/19/intel-can-supply-only-about-half-of-what-its-customers-want-that-s-a-better-problem-than-it-sounds/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Intel Can Supply Only About Half of What Its Customers Want. That's a Better Problem Than It Sounds. | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/19/sandisk-joins-the-s-and-p-100-on-monday-the-same-day-nike-leaves-it/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Sandisk Joins the S&amp;P 100 on Monday -- the Same Day Nike Leaves It | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Steel Dynamics signaled stronger-than-expected Q3 profitability on metal margin expansion and record shipments.

STLD Pre-Announces Q3 EPS of $5.34-$5.38, Tops Prior Quarters

<h2>$COIN jumps 12% to $194 as Bitcoin clears $80,941 and CFTC/SEC rulemaking boosts crypto outlook</h2><p>Coinbase Global shares surged 12% on Friday, Sept. 18, after Bitcoin cleared $80,941 and regulators advanced new crypto rulemaking that strengthened the case for broader adoption. The move came as investors responded to both the price breakout and a more constructive policy backdrop heading into the new trading week.</p><h3>What Happened</h3><p>$COIN was bid sharply higher as Bitcoin’s latest leg up reinforced momentum across the crypto complex. The catalyst was not just price action: the SEC also moved to create a temporary pathway for trading certain tokenized stocks, a step that brings 24/7-style market access closer and signals that regulators are building a crypto framework with the authority they already have.</p><p>The SEC’s order is temporary and conditional, but it is meaningful for sentiment. Tokenized stock holders must retain the same rights as traditional shareholders, and companies can object if their securities are represented as tokens. The exemption is designed to remain in force for five years, giving markets and regulators a test period while permanent rules are considered.</p><p>That matters for Coinbase because the stock tends to trade as a leveraged proxy for crypto market health and regulatory tone. A Bitcoin breakout above a major psychological level, paired with clearer rulemaking, removes a key overhang that has pressured crypto equities during periods of policy uncertainty.</p><h3>Analyst Take</h3><p>The setup is constructive for the sector in the near term. Traders tend to reward two things at once: rising underlying crypto prices and signs that Washington is moving from headline-driven uncertainty to a more defined rulebook.</p><p>For portfolio managers, the key point is that this was not only a speculative squeeze. The rally reflected a combination of spot-market strength and a concrete regulatory shift that could support higher trading activity, improved liquidity, and renewed investor appetite for crypto-linked names.</p><p>For active traders, $COIN’s move also confirms that the stock remains highly sensitive to Bitcoin’s direction. When BTC breaks out decisively, Coinbase often catches an outsized bid as sentiment expands across exchanges, brokers, and tokenization plays.</p><h3>What to Watch</h3><ul><li>Whether Bitcoin can hold above $80,941 and convert the breakout into a sustained trend.</li><li>Follow-through in crypto equities at the open of the new week, especially $COIN and other exchange-adjacent names.</li><li>Additional SEC and CFTC actions that could expand tokenized trading or clarify crypto market structure.</li><li>Any pushback from issuers or lawmakers, since the tokenized-stock framework is temporary and conditional.</li><li>Trading volume in Coinbase shares, which will show whether Friday’s move was a momentum burst or the start of a higher range.</li></ul>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/17/sec-clears-path-for-tokenized-stocks-bringing-24/7-trading-closer.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – SEC clears path for tokenized stocks, bringing 24/7 trading closer</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/17/securitize-jumps-after-regulators-greenlight-tokenized-us-stocks.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Securitize jumps after regulators greenlight tokenized U.S. stocks</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/18/why-xrp-is-up-today/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Why XRP Is Up Today | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://fortune.com/2026/09/18/onchain-finance-is-coming-to-wall-street-and-ignoring-it-is-no-longer-an-option/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fortune.com – Onchain finance is coming to Wall Street—and ignoring it is no longer an option | Fortune</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/19/shiba-inus-bull-market-price-potential-may-surpris/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Shiba Inu's Bull Market Price Potential May Surprise You | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/18/can-dogecoin-reach-1-by-year-end-heres-how-the-mem/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Can Dogecoin Reach $1 by Year-End? Here's How the Meme Coin Traded During the Last Election Year. | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Coinbase rallied as Bitcoin’s breakout and fresh SEC/CFTC action eased a major regulatory overhang for crypto equities.

COIN jumps 12% as Bitcoin tops $80,941 on crypto tailwinds

<h2>RARE jumps 12% on first FDA-approved Sanfilippo therapy</h2><p>Ultragenyx Pharmaceutical <strong>$RARE</strong> surged about 12% after the FDA approved Fayuvi for children with Sanfilippo syndrome type A, a rare and devastating pediatric disease that had no prior approved treatment. The move gives the biotech a fresh commercial catalyst in a high-unmet-need indication, even as the shares remain down roughly 37% for the year.</p><h3>What Happened</h3><p>The FDA granted full approval to Fayuvi, Ultragenyx’s gene therapy for pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The approval marks the first FDA-approved treatment for the disease, which progressively damages the brain and nervous system and has historically been managed only with symptom-focused care.</p><p>Investors treated the decision as more than a regulatory win. For a company like Ultragenyx, approval in an ultra-rare pediatric disorder can unlock a new commercial lane with strong pricing power and a clearer launch path, especially when the therapy is positioned as the first option in a field with no approved alternatives.</p><h3>Analyst Take</h3><p>The stock reaction fits the setup: binary regulatory risk is gone, and the market can now model launch timing, patient identification, reimbursement, and long-term uptake rather than approval odds. That matters most for $RARE because the company has been under pressure this year and needed a fresh catalyst to re-rate the name.</p><p>Still, traders should not confuse approval with immediate revenue acceleration. Gene therapies in very small populations can deliver meaningful per-patient economics, but launches can be slow, highly specialized, and dependent on center activation, payer access, and physician adoption.</p><h3>What to Watch</h3><ul><li>Launch execution and how quickly Ultragenyx can get Fayuvi into qualified treatment centers.</li><li>Reimbursement and payer behavior for a one-time, high-cost gene therapy.</li><li>Management commentary on patient demand, capacity, and commercial expectations.</li><li>Whether the approval changes sentiment around Ultragenyx’s broader pipeline and cash-flow profile.</li><li>Whether the recent bounce can hold after the initial approval pop fades.</li></ul><p>For active traders, $RARE is now a post-approval story: the trade shifts from regulatory speculation to commercial proof.</p>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.marketwatch.com/story/ultragenyx-pharmaceutical-rises-after-fda-approves-fayuvi-for-sanfilippo-syndrome-type-a-4c4d9859" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>marketwatch.com – Ultragenyx Pharmaceutical Rises After FDA Approves Fayuvi for Sanfilippo Syndrome Type A - MarketWatch</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/article/4947664-ultragenyx-pharmaceutical-inc-rare-discusses-fda-approval-of-fayuvi-as-first-treatment-for" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.marketwatch.com/story/health-care-up-on-drug-development-hopes-health-care-roundup-a5ec7acb" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>marketwatch.com – Health Care Up on Drug Development Hopes -- Health Care Roundup - MarketWatch</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc---rare-302881638.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>prnewswire.com – INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/news/4643397-rocket-pharma-stock-upgraded-needham" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ) | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.fool.com/investing/2026/09/18/should-you-buy-jazz-pharmaceuticals-stock-after-it/" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>fool.com – Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? | The Motley Fool</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Ultragenyx gets a new rare-disease revenue stream as Fayuvi clears the FDA, but the stock is still down sharply year to date.

RARE jumps 12% on first FDA-approved Sanfilippo therapy

<h2>Generac $GNRC Soars 30%+ on Amazon AI-Power Deal</h2><p>Generac shares surged more than 30% after the company disclosed a long-term supply agreement with Amazon for backup power generators tied to data centers. The deal immediately recast $GNRC as an AI infrastructure beneficiary, with investors reacting to the scale of the contract and the possibility of additional earnings upside.</p><h3>What Happened</h3><p>Amazon agreed to buy backup-data-center power generators from Generac in a deal that could reach $8 billion, with first deliveries expected to total $2.4 billion in 2027 and 2028. Generac also said it granted Amazon a warrant to acquire up to about 1.69 million shares at $200.9 apiece, adding a further strategic layer to the partnership.</p><p>The market response was immediate and aggressive. Shares jumped roughly 25% in extended trading on Wednesday and climbed more than 30% in the broader move as investors repriced Generac’s growth profile around AI-related power demand.</p><h3>Analyst Take</h3><p>Wall Street framed the announcement as more than a one-off contract win. Analysts said the Amazon agreement could meaningfully lift earnings expectations because it opens a path to large, multi-year revenue tied to data-center buildouts rather than just the company’s core residential generator business.</p><p>The deal also reinforced the idea that Generac is becoming a key supplier in the power stack supporting AI infrastructure. Some analysts pointed to the fact that the company had already secured a supply deal with a second hyperscaler earlier in the summer, suggesting Amazon is part of a broader customer trend rather than an isolated win.</p><h3>What to Watch</h3><p>The first question for traders is whether the stock has already run too far, too fast. A move of this size can create momentum follow-through, but it also raises the bar for future updates and leaves less room for disappointment if contract timing, margins, or execution slip.</p><p>Portfolio managers will want to watch how much of the announced value converts into actual shipments, when the 2027-2028 deliveries begin, and whether the warrant structure signals a longer strategic relationship beyond this initial order. Investors should also track whether other hyperscaler wins follow, because that would support the case that $GNRC is building a durable AI-power franchise rather than capturing a single headline deal.</p><ul><li>The Amazon contract is the main catalyst and the biggest near-term driver for sentiment.</li><li>The $2.4 billion initial delivery figure gives the market something tangible to model, but it is still forward-dated.</li><li>The warrant issuance adds strategic complexity and could matter if investors focus on dilution or long-term alignment.</li><li>After a 30%+ surge, the stock now trades on execution, not just announcement value.</li></ul>
<h3>Sources</h3>
<ul style="padding-left:1.25em;list-style:disc"><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.marketwatch.com/story/generacs-stock-soars-more-than-30-after-amazon-deal-cements-its-status-as-ai-power-player-a842b0dc" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>marketwatch.com – Generac’s stock soars more than 30% after Amazon deal cements company’s status as an AI-power player - MarketWatch</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/news/4643652-generac-soars-as-analysts-see-earnings-upside-from-amazon-deal" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Generac soars as analysts see earnings upside from Amazon deal (GNRC:NYSE) | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.cnbc.com/2026/09/16/amazon-obtains-right-to-buy-up-to-340m-of-generac-boosting-stock-.html" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>cnbc.com – Amazon obtains right to buy up to $340M of Generac, boosting stock</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.marketwatch.com/story/amazon-signs-2-4b-data-center-generator-deal-with-generac-70901551" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>marketwatch.com – Amazon Signs $2.4B Data Center Generator Deal With Generac - MarketWatch</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://seekingalpha.com/news/4643557-generac-surges-on-2_4b-amazon-data-center-deal" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>seekingalpha.com – Generac surges on $2.4B Amazon data-center deal (GNRC:NYSE) | Seeking Alpha</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li><li style="margin-bottom:.4em;line-height:1.35;"><a href="https://www.benzinga.com/trading-ideas/movers/26/09/61831070/generac-stock-soars-on-8-billion-amazon-data-center-deal" target="_blank" rel="noopener noreferrer nofollow" style="display:inline-flex;align-items:center;gap:.35rem;text-decoration:underline;text-underline-offset:2px;"><span>benzinga.com – Generac Stock Soars on $8 Billion Amazon Data Center Deal - Generac Holdings (NYSE:GNRC) - Benzinga</span><svg xmlns="http://www.w3.org/2000/svg" width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true" focusable="false" style="flex-shrink:0;opacity:.9"><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1 2-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg></a></li></ul>

Generac’s Amazon data-center pact has turned it into a higher-stakes AI infrastructure play, but the post-surge setup now tests whether the upside is already priced in.

Signal over noise